Diligence memo · auto-generated · as of July 2, 2026

BELLUS Health Inc.

BELLUS Health Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

BELLUS Health Inc. operates in Biotechnology, based in LAVAL.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

BELLUS Health Inc. has raised $34M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $24M on 2018-12-18.

Most recent recorded round closed around 2018-12-18.

Valuation (modeled)modeled

Provath models BELLUS Health Inc. at approximately $951M (range $48M–$3.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.20× the median modeled value of Series B Biotechnology companies in 2016–2018 (101 peers) — value vs value, same stage and era. Within the normal band (120% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 6 months.

Last raise 7.5 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 18.6× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 76% of Biotechnology peers (4293 compared).

Modeled value ranks above 89% of those peers.

Closest niche peers: Liquid BioScience, Inc., Amphivena Therapeutics, Inc., Tracon Pharmaceuticals, Inc., Tetra Discovery Partners, Inc., ECM Therapeutics, Inc..

Peoplefiled

11 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.